Clean Yield Group Has $3.40 Million Stake in Novo Nordisk A/S (NVO)

Clean Yield Group cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 79,138 shares of the company’s stock after selling 785 shares during the period. Novo Nordisk A/S comprises 1.4% of Clean Yield Group’s portfolio, making the stock its 28th largest position. Clean Yield Group’s holdings in Novo Nordisk A/S were worth $3,401,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Security Asset Management boosted its position in shares of Novo Nordisk A/S by 2.1% in the fourth quarter. Security Asset Management now owns 50,067 shares of the company’s stock valued at $1,795,000 after buying an additional 1,012 shares during the period. Cim LLC boosted its position in shares of Novo Nordisk A/S by 0.5% in the first quarter. Cim LLC now owns 196,121 shares of the company’s stock valued at $6,723,000 after buying an additional 1,045 shares during the period. Comerica Bank boosted its position in shares of Novo Nordisk A/S by 6.3% in the first quarter. Comerica Bank now owns 205,457 shares of the company’s stock valued at $7,967,000 after buying an additional 12,176 shares during the period. ST Germain D J Co. Inc. boosted its position in shares of Novo Nordisk A/S by 8.0% in the first quarter. ST Germain D J Co. Inc. now owns 194,565 shares of the company’s stock valued at $6,670,000 after buying an additional 14,414 shares during the period. Finally, Cabot Wealth Management Inc. boosted its position in shares of Novo Nordisk A/S by 3.9% in the first quarter. Cabot Wealth Management Inc. now owns 108,656 shares of the company’s stock valued at $3,725,000 after buying an additional 4,066 shares during the period. 6.34% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S (NYSE NVO) traded up 0.198% during trading on Monday, reaching $43.065. The company had a trading volume of 747,214 shares. The firm has a 50-day moving average of $42.51 and a 200-day moving average of $37.36. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $57.41. The stock has a market capitalization of $107.48 billion, a price-to-earnings ratio of 18.287 and a beta of 0.63.

WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2723216/clean-yield-group-has-3-40-million-stake-in-novo-nordisk-as-nvo.html.

Several equities analysts have recently issued reports on NVO shares. HSBC Holdings plc cut Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Monday, March 20th. BidaskClub cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Finally, TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


Leave a Reply

© 2006-2017 Ticker Report. Google+.